Memedovich K Ally, Shaheen Abdel Aziz, Swain Mark G, Clement Fiona M
Department of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
O'Brien Institute of Public Health, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Gastro Hep Adv. 2024 Jun 4;3(7):965-972. doi: 10.1016/j.gastha.2024.05.010. eCollection 2024.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease worldwide. The current and projected cost of treating individuals with MASLD in Canada remains unknown. Our objective was to calculate the projected liver-specific and total health-care costs for people living with MASLD in Canada from 2020 to 2050.
The health-care usage of a cohort of patients diagnosed with MASLD in Calgary, Alberta was calculated using administrative data. Liver-specific encounters were identified and the average costs per year per patient were calculated. Projected costs were calculated by multiplying the average cost per patient within each health state by the projected prevalence of each health state.
There were 6358 patients in the cohort. The annual average liver-specific cost per patient was $7.02 for F0/F1, $35.30 for F2, $60.46 for F3, and $72.55 for F4. The projected Canada-wide liver-specific cost was $85.5 million in 2020 and was expected to increase by $51 million by 2050. The average annual total health-care cost per patient was $397.90 for F0/F1, $781.53 for F2, $2881.84 for F3, and $1598.82 for F4. Thus, the projected Canada-wide total health-care cost was $3.76 billion in 2020 and was expected to increase by almost $2 billion by 2050.
These estimates underscore the need for a MASLD framework that focuses on both prevention and innovative care models to change the predicted trajectory of health-care costs.
代谢功能障碍相关脂肪性肝病（MASLD）是全球慢性肝病最常见的病因。目前及预计在加拿大治疗MASLD患者的费用尚不清楚。我们的目标是计算2020年至2050年加拿大MASLD患者的肝脏特异性和总体医疗保健费用预测值。
利用行政数据计算艾伯塔省卡尔加里市一组被诊断为MASLD患者的医疗保健使用情况。确定肝脏特异性诊疗情况，并计算每位患者每年的平均费用。通过将每个健康状态下每位患者的平均费用乘以每个健康状态的预测患病率来计算预测费用。
该队列中有6358名患者。F0/F1期每位患者每年的肝脏特异性平均费用为7.02美元，F2期为35.30美元，F3期为60.46美元，F4期为72.55美元。预计2020年加拿大全国肝脏特异性费用为8550万美元，到2050年预计将增加5100万美元。F0/F1期每位患者每年的总体医疗保健平均费用为397.90美元，F2期为781.53美元，F3期为2881.84美元，F4期为1598.82美元。因此，预计2020年加拿大全国总体医疗保健费用为37.6亿美元，到2050年预计将增加近20亿美元。
这些估计强调了需要一个MASLD框架，该框架既要关注预防，也要关注创新护理模式，以改变预测的医疗保健费用轨迹。
